NEWRON PHARMACEUTICALS S.P.A.

NEWRON PHARMACEUTICALS S.P.A.

Share · IT0004147952 · A0LF18 (XSWX)
Overview
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of NEWRON PHARMACEUTICALS S.P.A.
No Price
Closing Price XSWX 28.04.2026: 15,04 CHF
28.04.2026 14:55
Current Prices from NEWRON PHARMACEUTICALS S.P.A.
ExchangeTickerCurrencyLast TradePriceDaily Change
XSWX: SIX
SIX
NWRN.SW
CHF
28.04.2026 14:55
15,04 CHF
-0,26 CHF
-1,67 %
XETR: XETRA
XETRA
NP5.DE
EUR
28.04.2026 14:40
16,20 EUR
-0,45 EUR
-2,70 %
XLON: London
London
0QOI.L
CHF
28.04.2026 13:58
15,02 CHF
-0,28 CHF
-1,80 %
XDQU: Quotrix
Quotrix
NPSAAE52.DUSD
EUR
28.04.2026 07:03
16,25 EUR
-0,80 EUR
-4,69 %
XDUS: Düsseldorf
Düsseldorf
NPSAAE52.DUSB
EUR
27.04.2026 17:31
16,55 EUR
-0,50 EUR
-2,93 %
XHAM: Hamburg
Hamburg
NPSAAE52.HAMB
EUR
23.04.2026 06:12
17,90 EUR
-
Company Profile for NEWRON PHARMACEUTICALS S.P.A. Share
Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease, as well as develops Xadago for the treatment of levodopa induced dyskinesia. It also develops Evenamide for Schizophrenia and treatment resistant schizophrenia; and Ralfinamide for orphan indication in neuropathic pain. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.

Company Data

Name NEWRON PHARMACEUTICALS S.P.A.
Company Newron Pharmaceuticals S.p.A.
Website https://www.newron.com
Primary Exchange XSWX SIX
WKN A0LF18
ISIN IT0004147952
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Stefan Weber
Market Capitalization 314 Mio
Country Italy
Currency CHF
Employees 0,0 T
Address Via Antonio Meucci 3, 20091 Bresso
IPO Date 2006-12-12

Ticker Symbols

Name Symbol
Düsseldorf NPSAAE52.DUSB
Frankfurt NP5.F
Hamburg NPSAAE52.HAMB
London 0QOI.L
Quotrix NPSAAE52.DUSD
SIX NWRN.SW
XETRA NP5.DE
More Shares
Investors who hold NEWRON PHARMACEUTICALS S.P.A. also have the following shares in their portfolio:
CA NEXT BANK 21/31 MTN
CA NEXT BANK 21/31 MTN Bond
ENI FINAN.INTL. 08-28 MTN
ENI FINAN.INTL. 08-28 MTN Bond